On April 1st, 2026, a landmark shift occurred in the Brazilian private healthcare landscape as the National Supplementary Health Agency (ANS) officially included robotic-assisted radical prostatectomy in its List of Procedures and Events. Following the approval of Normative Resolution No. 654, health insurance providers are now mandated to cover this technology for patients with localized or locally advanced prostate cancer.
Evidence Supporting Robotic Prostatectomy
The decision is backed by a robust body of evidence highlighting the advantages of the robotic platform. Studies, such as the systematic review and meta-analysis published in European Urology, demonstrate that robotic-assisted radical prostatectomy significantly reduces positive surgical margins and perioperative complications. Compared to open and laparoscopic techniques, the robotic approach offers superior visualization and precision, resulting in lower blood loss and faster recovery of urinary continence and sexual function – key metrics for patient quality of life.
This resolution marks a turning point for medical technology in Brazil. While robotic surgery has been available in premium hospitals for over a decade, its costs were previously largely restricted to out-of-pocket payments or legal disputes. By granting mandatory coverage, the ANS democratizes access to these superior surgical outcomes within the private sector.
Challenges in the Public Healthcare System
However, a significant disparity remains regarding the Unified Health System (SUS). Although some public institutions and university hospitals already possess robotic platforms, surgical volume remains critically low due to high maintenance costs and expensive disposables. While private patients now benefit from mandated robotic precision, the public sector still faces infrastructure and funding challenges in offering the same standard of care at scale. Bridging this gap is essential to ensure that surgical innovation in oncology is not a privilege, but a nationwide standard.
Expanding the Role of Robotic Surgery in Oncology
The inclusion of prostatectomy is seen as a significant precedent that may facilitate the evaluation of other procedures. A prime example for future consideration is the surgical treatment of rectal cancer. Data from the REAL Trial (Robotic Versus Laparoscopic Resection for Rectal Cancer) has already provided high-quality evidence demonstrating that the robotic platform can offer clinical advantages in pelvic dissection and the preservation of autonomic nerves. This suggests a promising pathway for the eventual integration of robotic precision into other complex oncological specialties.